STAT Plus: With Grail in its sights, Illumina pursues grand vision that could reshape the business of cancer diagnoses
Illumina, the dominant maker of machines to sequence DNA, is in talks to purchase Grail, a developer of a blood test to detect cancer that uses Illumina’s technology.
The discussions were first reported by Bloomberg News, and confirmed to STAT by a person with knowledge of the talks. The discussions could still fall apart at any time.
Continue to STAT Plus to read the full story…
